Linotroban

The aim of this study was to evaluate the renal protective effect of linotroban, a thromboxane A2 receptor antagonist, in 25 patients with malignant tumours scheduled for cisplatin therapy. Cisplatin was administered 1 h after the start of a 24‐h continuous infusion of linotroban or placebo. Glomerular filtration rate and effective renal plasma flow were measured. Infusions of cisplatin decreased glomerular filtration rate by 17 ± 25 mL min−1 (P = 0.049 vs. baseline) and effective renal plasma flow by 94 ± 150 mL min−1 (P = 0.049 vs. baseline) in the placebo group. In the linotroban group a decrease in glomerular filtration rate by 11 ± 18 mL min−1 (P = 0.050 vs. baseline) and in effective renal plasma flow by 26 ± 63 mL min−1 (P = 0.2 vs. baseline) was noted. However, no difference was noted between groups in response to treatment. Our findings indicate that linotroban may not be useful for prevention of cisplatin's acute nephrotoxic effects.

This paper reports the results of experiments designed to determine the effect of linotroban (CAS 141443-73-4) a selective thromboxane (TXA2) receptor antagonist with novel antithrombotic activity, on renal function in conscious male and female rats. Linotroban was administered subcutaneously at doses of 0, 6, 24, 48 and 96 mg/kg/24 h by osmotic minipumps over 6 days. Inulin (Inutest) and para-aminohippuric acid (PAH) clearances were determined on the last day of linotroban treatment. These agents were delivered by a slow release tablet planted s.c. five days after the start of the linotroban treatment. Linotroban did not significantly alter renal functions, although there was a significant difference in GFR (glomerular filtration rate) for male and female rats receiving the highest dose. Linotroban is well tolerated but the difference in renal function between male and female rats at the highest dose may reflect a threshold of renal tolerance.